Our top pick for
Building a portfolio
Celyad Oncology SA is a biotechnology business based in the US. Celyad Oncology shares (CYAD) are listed on the NASDAQ and all prices are listed in US Dollars. Celyad Oncology employs 87 staff and has a trailing 12-month revenue of around USD$5,000.
|52-week range||USD$6.81 - USD$13.01|
|50-day moving average||USD$7.3461|
|200-day moving average||USD$8.1769|
|Wall St. target price||USD$19.14|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-7.007|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$5,000|
|Return on assets TTM||-21.04%|
|Return on equity TTM||-44.91%|
|Market capitalisation||USD$102.3 million|
TTM: trailing 12 months
There are currently 209,905 Celyad Oncology shares held short by investors – that's known as Celyad Oncology's "short interest". This figure is 0.2% down from 210,285 last month.
There are a few different ways that this level of interest in shorting Celyad Oncology shares can be evaluated.
Celyad Oncology's "short interest ratio" (SIR) is the quantity of Celyad Oncology shares currently shorted divided by the average quantity of Celyad Oncology shares traded daily (recently around 12599.339735894). Celyad Oncology's SIR currently stands at 16.66. In other words for every 100,000 Celyad Oncology shares traded daily on the market, roughly 16660 shares are currently held short.
However Celyad Oncology's short interest can also be evaluated against the total number of Celyad Oncology shares, or, against the total number of tradable Celyad Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Celyad Oncology's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Celyad Oncology shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Celyad Oncology shares, roughly 0 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Celyad Oncology.
Find out more about how you can short Celyad Oncology stock.
We're not expecting Celyad Oncology to pay a dividend over the next 12 months.
Over the last 12 months, Celyad Oncology's shares have ranged in value from as little as $6.81 up to $13.01. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celyad Oncology's is 1.4889. This would suggest that Celyad Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. .
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.